Cagrilintide vs Tirzepatide: How These Two Weight-Loss Drugs Compare

Cagrilintide and tirzepatide belong to different drug classes, and that single fact shapes every comparison between them. Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist sold as Mounjaro and Zepbound, while cagrilintide is an investigational amylin analog that has not been approved for any human use in the United States. Because no trial has ever compared cagrilintide alone with tirzepatide head-to-head, all existing comparisons rely on separate studies and indirect data.

Cagrilintide vs Tirzepatide at a Glance

The table below summarizes the practical differences most people want to understand before reading further into either drug.

Feature	Cagrilintide	Tirzepatide
Drug class	Long-acting amylin analog	Dual GIP and GLP-1 receptor agonist
Brand names	None approved; studied with semaglutide as CagriSema	Mounjaro (type 2 diabetes), Zepbound (weight management)
FDA status	Not approved for human use	Approved for type 2 diabetes and chronic weight management
Route and schedule	Once-weekly subcutaneous injection (in trials)	Once-weekly subcutaneous injection
Doses studied	Up to 4.5 mg as monotherapy; 2.4 mg in CagriSema	5 mg, 10 mg, or 15 mg weekly
Reported weight loss	About 10% with monotherapy at 26 weeks; about 22.7% with CagriSema at 68 weeks	About 20.9% at 72 weeks with 15 mg in SURMOUNT-1
Developer	Novo Nordisk	Eli Lilly

How Cagrilintide and Tirzepatide Work Differently

Cagrilintide mimics amylin, a hormone the pancreas releases alongside insulin after a meal. It binds amylin receptors in the brain to increase fullness, slow stomach emptying, and reduce the drive to eat.

Tirzepatide activates two gut-hormone receptors at once: GIP and GLP-1. That dual action improves blood sugar control, delays gastric emptying, and lowers appetite through several pathways.

Because the two drugs hit different receptor systems, researchers have explored whether an amylin-based drug adds something that GLP-1-based drugs alone do not. Novo Nordisk paired cagrilintide with semaglutide for exactly that reason.

Anyone tracking the investigational pipeline will notice the same question being asked about other molecules, including in comparisons such as cagrilintide vs retatrutide, where an amylin analog is measured against a triple-agonist still in development.

Weight Loss Results: What the Trials Actually Show

Direct cagrilintide vs tirzepatide data do not exist. What exists instead are separate trials with different designs, populations, and durations.

• Cagrilintide monotherapy: A phase 2 trial reported roughly 10% average weight loss at 26 weeks in adults with obesity, with gastrointestinal side effects driving many discontinuations.
• CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg): The REDEFINE 1 phase 3 trial reported about 22.7% mean weight loss at 68 weeks, compared with roughly 16.1% for semaglutide alone and about 2.3% for placebo.
• Tirzepatide 15 mg: The SURMOUNT-1 trial reported about 20.9% mean weight loss at 72 weeks in adults with obesity but without diabetes.
• Tirzepatide vs. semaglutide: In SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide 2.4 mg, which makes the debate over tirzepatide vs semaglutide which is better for weight loss one of the few arguments with true head-to-head data behind it.

Cross-trial percentages should never be read as a scoreboard. Differences in study length, starting weight, diabetes status, and how missing data are handled can shift results by several percentage points.

Side Effects, Safety, and Approval Status

Both drugs act on appetite and digestion, so both produce similar gastrointestinal effects.

• Nausea, vomiting, diarrhea, and constipation are the most common complaints reported for cagrilintide and tirzepatide.
• Tirzepatide carries a boxed warning about thyroid C-cell tumors observed in rodents and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.
• Pancreatitis, gallbladder disease, and low blood sugar (especially with insulin or sulfonylureas) are recognized risks of tirzepatide.
• Cagrilintide's long-term safety profile is still being characterized because the drug remains investigational.

Neither drug is appropriate during pregnancy, and neither should be started without a prescription and medical supervision. Unapproved or research-grade peptides sold online carry extra risks, including unknown purity, incorrect dosing, and no regulatory oversight.

What Reddit Threads Get Right and Wrong

Searches for cagrilintide vs tirzepatide reddit usually land in forums where people share self-reported results, sourcing tips, and personal dosing experiments. Those anecdotes can help you understand what side effects feel like day to day, but they are not clinical evidence.

The most common mistake in those threads is treating an investigational drug and an FDA-approved drug as equally available options. Cagrilintide can only be obtained legally through a clinical trial, and posts describing an online purchase are describing a research chemical, not a medicine.

The same caution applies to other compounds that show up in those discussions, including the comparison labeled mots-c peptide vs tirzepatide and the question of lipo-c vs tirzepatide, both of which mix unapproved products with an approved prescription drug.

A three-way look at cagrilintide vs retatrutide vs tirzepatide mostly makes the same point: two of those three drugs are still experimental, and only tirzepatide has cleared regulatory review.

Bottom Line: Which One Is Better?

If the question is which drug is available, proven, and approved today, the answer is tirzepatide. It has completed phase 3 trials, holds FDA approval for two indications, and has years of real-world use behind it.

If the question is which one is more promising for future weight loss, that debate is unresolved. CagriSema's phase 3 results are competitive with tirzepatide's, but cagrilintide by itself has not been tested against tirzepatide, and no head-to-head trial is currently reported.

Anyone considering either drug should discuss goals, risks, and alternatives with a licensed healthcare professional instead of relying on forum posts or cross-trial percentages.

COMMON QUESTIONS

Frequently Asked Questions

Is cagrilintide better than tirzepatide for weight loss?

No head-to-head trial answers this question, so the honest answer is that it is unknown. CagriSema, which combines cagrilintide with semaglutide, produced about 22.7% weight loss at 68 weeks in REDEFINE 1, while tirzepatide 15 mg produced about 20.9% at 72 weeks in SURMOUNT-1, but those numbers come from different trials and cannot be compared directly. Cagrilintide on its own remains investigational.

Is cagrilintide FDA approved?

No. Cagrilintide is not FDA-approved for any human use in the United States. It is available only through clinical trials, and products marketed online as cagrilintide are research chemicals that are not intended for human consumption.

Can cagrilintide and tirzepatide be used together?

No approved combination exists, and the two drugs have not been studied together in humans. Both slow gastric emptying and can cause nausea, vomiting, and constipation, so combining them could intensify side effects. Any such combination should only be considered under medical supervision in a research setting.